KSX01
/ TCRx Therap
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
April 23, 2025
Phase I trial of personalized AI-identified TCR-transduced T cell therapy in advanced solid tumors.
(ASCO 2025)
- P1 | "Patients received preconditioning with cyclophosphamide (500 mg/m²/day) and fludarabine (30 mg/m²/day) for 3 days, followed by intravenous infusion of KSX01 TCR-T cells at two dose levels (5×10⁹ ± 30% and 1×10¹⁰ ± 30% cells)...One patient developed Grade 2 CRS, resolved with tocilizumab... The first-in-human phase I trial of KSX01 TCR-T cell therapy demonstrated promising safety and efficacy in patients with advanced solid tumors. TCR-XFinder enabled rapid identification of personalized tumor-reactive TCRs, supporting the clinical feasibility of this approach. Further studies are warranted to explore optimal dosing and combination strategies to maximize clinical benefit."
Metastases • P1 data • Alveolar Soft Tissue Sarcoma • Clear Cell Renal Cell Carcinoma • Colon Cancer • Colorectal Cancer • Genito-urinary Cancer • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • CRP • IFNG • IL10 • IL4 • IL6 • TNFA
July 19, 2024
A phase I study of personalized KSX01-TCRT therapy for advanced solid tumor and its mechanisms
(ESMO 2024)
- P1 | "AI-driven TCR identification as a promising method significantly shortens the drug manufacture time in personalized TCR T therapy. KSX01-TCRT is well tolerated and offers clinical benefits for multiple advanced solid tumors with no limit of HLA restriction or target expression."
IO biomarker • Metastases • P1 data • Oncology • Solid Tumor
November 29, 2023
Single Arm Clinical Study on the Safety and Efficacy of Personalized KSX01-TCRT in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=12 | Recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Metastases • New P1 trial • Oncology • Solid Tumor
April 13, 2023
KSX01-TCRT Injection Project in Solid Tumors
(clinicaltrials.gov)
- P1 | N=50 | Recruiting | Sponsor: TCRx Therapeutics Co.Ltd
New P1 trial • Oncology • Solid Tumor
1 to 4
Of
4
Go to page
1